Following the discovery of mTOR complexes, the mTOR hyperactivity and/or sensitivity of tumor cells against mTOR inhibitors, quantitative changes in the mTOR signaling pathway elements, target proteins, and their active forms have been described and partially characterized in various tumor types by the end of the last century and early 2000 s (detailed in Figure 5). This evidence concerns the gene MTOR and neoplasm.